MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
82.07
-2.12
-2.52%
Pre Market: 82.16 +0.09 +0.11% 04:46 12/18 EST
OPEN
83.36
PREV CLOSE
84.19
HIGH
84.23
LOW
80.78
VOLUME
19
TURNOVER
0
52 WEEK HIGH
103.00
52 WEEK LOW
19.45
MARKET CAP
6.55B
P/E (TTM)
-22.8334
1D
5D
1M
3M
1Y
5Y
1D
Kymera Therapeutics (KYMR) Gets a Buy from Wells Fargo
TipRanks · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Amazon,  Palo Alto Networks
Reuters · 1d ago
BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026
Reuters · 1d ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
Kymera Therapeutics Price Target Raised to $103.00/Share From $70.00 by RBC Capital
Dow Jones · 2d ago
Kymera Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 2d ago
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.